Basit öğe kaydını göster

dc.contributor.authorEsin, Ece
dc.contributor.authorÇakmak Öksüzoǧlu, Berna
dc.contributor.authorBilici, Ahmet Erkan
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorKöstek, Osman
dc.contributor.authorKaplan, Mehmet Ali
dc.contributor.authorAksoy, Sercan
dc.contributor.authorAktaş, Burak Yasin
dc.contributor.authorÖzdemir, Özlem
dc.contributor.authorAlacacıoğlu, Ahmet
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorSümbül, Ahmet Taner
dc.contributor.authorSakin, Abdullah
dc.contributor.authorPaydaş, Semra
dc.contributor.authorYetişir, Ersin
dc.contributor.authorEr, Özlem
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorYıldırım, Nilgün
dc.contributor.authorŞakalar, Teoman
dc.contributor.authorDemir, Hacer
dc.contributor.authorArtaç¸, Mehmet
dc.contributor.authorKaraaǧaç, Mustafa
dc.contributor.authorHarputluoǧlu, Hakan
dc.contributor.authorBilen, Ebru
dc.contributor.authorErdur, Erkan
dc.contributor.authorDeǧirmencioǧlu, Serkan
dc.contributor.authorAliyev, Altay
dc.contributor.authorÇil, Timuçin
dc.contributor.authorOlgun, Polat
dc.contributor.authorBaşaran, Gül Atalay
dc.contributor.authorGümüşay, Özge
dc.contributor.authorDemir, Atakan
dc.contributor.authorTanrıkulu, Eda
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorİmamoğlu, İnanç
dc.contributor.authorOyan, Başak
dc.contributor.authorÇetin, Bülent Eren
dc.contributor.authorHaksöyler, Veysel
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorErtürk, İsmail
dc.contributor.authorEvrensel, Türkkan
dc.contributor.authorYılmaz, Hasan
dc.contributor.authorBeypınar, İsmail
dc.contributor.authorKoçer, Murat
dc.contributor.authorPilancı, Kezban Nur
dc.contributor.authorŞeker, Mesut Metin
dc.contributor.authorÜrün, Yüksel
dc.contributor.authorYıldırım, Nuriye O.
dc.contributor.authorEren, Tülay
dc.contributor.authorDemirci, Umut
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:50:58Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:50:58Z
dc.date.issued2019en_US
dc.identifier.citationEsin, E., Çakmak Öksüzoğlu, B., Bilici, A. E., Çiçin, İ., Köstek, O., Kaplan M. A. … Demirci, U. (2019). Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomes. Cancer Chemotherapy and Pharmacology, 83(1), 131-143. https://dx.doi.org/10.1007/s00280-018-3712-7en_US
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.urihttps://dx.doi.org/10.1007/s00280-018-3712-7
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2118
dc.descriptionWOS: 000458407200014en_US
dc.descriptionPubMed ID: 30377778en_US
dc.description.abstractPurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers.ResultsMedian age was 51 (22-82). Median PFS was 28.5months, while median OS was 40.3months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8m vs. 28.5m; p=0.002) and OS (26.7m vs. 40.3m; p=0.009). Patients older than 65years of age (n: 42, 13.2%) had significantly lower OS results (19.8m vs. 40.3m; p=0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure.ConclusionsOur RLP trial included only visceral metastatic, trastuzumab-naive BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.en_US
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectPertuzumaben_US
dc.subjectTrastuzumaben_US
dc.subjectAntiher2en_US
dc.subjectVisceral Metastasisen_US
dc.subjectBrain Metastasisen_US
dc.titlePertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: Real-life practice outcomesen_US
dc.typearticleen_US
dc.relation.ispartofCancer Chemotherapy and Pharmacologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume83en_US
dc.identifier.issue1en_US
dc.identifier.startpage131en_US
dc.identifier.endpage143en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1007/s00280-018-3712-7en_US
dc.identifier.wosqualityQ3en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster